BREXIT Here we go, like lemmings over the cliff edge ...



CytoDyn has multiple shots on goal with its flagship drug leronlimab as cure...

Leronlimab is an antiviral agent candidate with fewer side effects, lower toxicity and less...

13 hours, 17 minutes ago

Dyadic on course to disrupt the status quo in manufacturing biologic...

The company applies its proprietary C1 gene expression platform to speed up the development of...

6 days, 2 hours ago

Aequus Pharmaceuticals has the right Rx to bring new drugs to the Canadian...

It takes medications already available in the US or elsewhere and licenses or acquires the...

1 week, 3 days ago

Paradigm Biopharmaceuticals makes new breakthrough for iPPS, shares rise

New clinical trial data shows that its trial drug Zilosul (iPPS) also reduces knee cartilage...

3 weeks, 1 day ago


hVIVO PLC's 2020 pipeline 'looking strong' as it expands service offerings

hVIVO PLC's (LON:HVO) executive chairman Trevor Phillips tells Proactive London's Andrew Scott the business is now better positioned to be profitable next year. The creator of pioneering human disease models based upon viral challenge generated revenues of £5.9mln in the six months ended June...

9 hours, 41 minutes ago

Join Proactive

Get ahead of the curve

First with the equities news

Get our market previews and stories before the main networks.

Widest with the analysis

Not just the FTSE. Read about
opportunities from the whole
equities market.

Closest the source

Hear directors at first-hand
or meet them in person at our events.

In at the start

Watch IPOs and access on the same terms as the institutions.